-
Stephanie Scarmo,
Yelena Afanasyeva,
Per Lenner,
Karen Koenig,
Ronald Horst, Tess Clendenen,
Alan Arslan,
Yu Chen,
Goran Hallmans,
Eva Lundin,
Sabina Rinaldi,
Paolo Toniolo,
Roy Shore,
Anne Zeleniuch-Jacquotte
[show abstract]
[hide abstract]
ABSTRACT: INTRODUCTION: Experimental evidence suggests a protective role for circulating 25-hydroxyvitamin D (25(OH)D) in breast cancer development, but the results of epidemiological studies have been inconsistent. METHODS: We conducted a case-control study nested within two prospective cohorts, the New York University Women's Health Study and the Northern Sweden Mammary Screening Cohort. Blood samples were collected at enrollment, and women were followed up for breast cancer ascertainment. A total of 1,585 incident breast cancer cases were individually-matched to 2,940 controls. Of these subjects, 678 cases and 1,208 controls contributed two repeat blood samples, at least one year apart. Circulating levels of 25(OH)D were measured, and multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. RESULTS: No association was observed between circulating levels of 25(OH)D and overall breast cancer risk (multivariate-adjusted model OR = 0.94, 95% CI = 0.76-1.16 for the highest vs. lowest quintile, ptrend=0.30). The temporal reliability of 25(OH)D measured in repeat blood samples was high (intraclass correlation coefficients for season-adjusted 25(OH)D > 0.70) . An inverse association between 25(OH)D levels and breast cancer risk was observed among women who were [less than or equal to] 45 years of age (ORQ5-Q1 = 0.48, 95% CI = 0.30-0.79, ptrend=0.01) or premenopausal at enrollment (ORQ5-Q1 = 0.67, 95% CI = 0.48-0.92, ptrend=0.03). CONCLUSIONS: Circulating 25(OH)D levels were not associated with breast cancer risk overall, although we could not exclude the possibility of a protective effect in younger women. Recommendations regarding vitamin D supplementation should be based on considerations other than breast cancer prevention.
Breast cancer research: BCR 02/2013; 15(1):R15. · 5.24 Impact Factor
-
Tess Clendenen,
Alan Arslan,
Anna Lokshin,
Annika Idahl,
Göran Hallmans,
Karen Koenig,
Adele Marrangoni,
Brian Nolen,
Nina Ohlson,
Anne Zeleniuch-Jacquotte,
Eva Lundin
[show abstract]
[hide abstract]
ABSTRACT: Abstract Background Cytokines are involved in the development of chronic diseases, including cancer. It is important to evaluate the temporal reproducibility of cytokines in plasma prior to conducting epidemiologic studies utilizing these markers. Findings We assessed the temporal reliability of CRP, 22 cytokines and their soluble receptors (IL-1α, IL-1β, IL-1RA, IL-2, sIL-2R, IL-4, IL-5, IL-6, sIL-6R, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, TNFα, sTNF-R1, sTNF-R2, IFNα, IFNγ) and eight growth factors (GM-CSF, EGF, bFGF, G-CSF, HGF, VEGF, EGFR, ErbB2) in repeated EDTA plasma samples collected an average of two years apart from 18 healthy women (age range: 42-62) enrolled in a prospective cohort study. We also estimated the correlation between serum and plasma biomarker levels using 18 paired clinical samples from postmenopausal women (age range: 75-86). Twenty-six assays were able to detect their analytes in at least 70% of samples. Of those 26 assays, we observed moderate to high intra-class correlation coefficients (ICCs)(ranging from 0.53-0.89) for 22 assays, and low ICCs (0-0.47) for four assays. Serum and plasma levels were highly correlated (r > 0.6) for most markers, except for seven assays (r < 0.5). Conclusions For 22 of the 31 biomarkers, a single plasma measurement is a reliable estimate of a woman's average level over a two-year period.
BMC Research Notes. 01/2010;
-
Eva Lundin,
Laure Dossus, Tess Clendenen,
Vittorio Krogh,
Kjell Grankvist,
Marianne Wulff,
Sabina Sieri,
Alan A Arslan,
Per Lenner,
Franco Berrino,
Goran Hallmans,
Anne Zeleniuch-Jacquotte,
Paolo Toniolo,
Annekatrin Lukanova
[show abstract]
[hide abstract]
ABSTRACT: Inflammatory processes may influence the risk of epithelial ovarian cancer, but available epidemiological evidence is limited and indirect. Circulating C-reactive protein (CRP), a sensitive marker of inflammation, may serve as a direct biological marker of an underlying association.
The association between ovarian cancer risk and pre-diagnostic circulating CRP was tested in a case-control study nested within three prospective cohorts from Sweden, USA, and Italy. The study included 237 cases and 427 individually matched controls. CRP was measured in stored blood samples by high-sensitivity immunoturbidimetric assay. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by conditional logistic regression.
Overall, CRP was not related to risk of ovarian cancer. However, a marked increase in risk was observed for CRP concentrations >10 mg/l: OR (95% CI) 4.4 (1.8-10.9), which remained significant after limiting analyses to cases diagnosed more than two or five years after blood donation (OR 3.0 (1.2-8.0) and 3.6 (1.0-13.2), respectively). Risk of mucinous tumors increased with high CRP, but the number of cases in this analysis was small.
Study results offer additional support to the concept that chronic inflammation plays a role in epithelial ovarian cancer.
Cancer Causes and Control 03/2009; 20(7):1151-9. · 2.88 Impact Factor
